Novelix Pharmaceuticals Signs 5-Year Lab Lease Deal at Genome Valley

Trimurthi (formerly Trimurthi Limited) has announced the execution of a lease deed for laboratory space to establish its research and development facility. The company informed BSE Limited about this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Lease Agreement Details

Trimurthi signed the lease deed with Neovantage Innovation Park Private Limited for laboratory space at the prestigious Genome Valley in Hyderabad, positioning the company in one of India's prominent biotechnology hubs.

Parameter	Details
Lease Partner	Neovantage Innovation Park Private Limited
Space Area	3,890 square feet
Location	Genome Valley, Hyderabad
Lease Duration	5 years
Commencement Date	January 1, 2026

Financial Terms and Structure

The lease agreement includes specific financial arrangements designed to accommodate long-term operations. The rental structure incorporates annual escalations to account for market dynamics over the lease period.

Financial Component	Amount
Monthly Rent	₹272,300.00
Additional Charges	Plus applicable taxes
Annual Increase	5% per year

Strategic Purpose and Operations

The leased facility will serve as the foundation for Trimurthi's research and development operations. The company plans to establish comprehensive R&D capabilities focusing on pharmaceutical and biotechnology research development, along with formulations.

The laboratory space will enable the company to:

Conduct pharmaceutical research and development activities
Pursue biotechnology research initiatives
Develop new formulations
Enhance its research capabilities in the pharmaceutical sector

Regulatory Compliance

Trimurthi confirmed that this lease arrangement does not constitute a related party transaction. The company stated that promoters, promoter groups, or group companies have no interest in Neovantage Innovation Park Private Limited, ensuring the transaction maintains arm's length principles.

The company has fulfilled its disclosure obligations under SEBI regulations and requested BSE Limited to disseminate this information through its website for investor awareness.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.99%	+0.20%	+11.22%	+96.65%	+127.55%	+127.55%

Trimurthi has issued a formal notice for its Extraordinary General Meeting (EGM) scheduled for January 9, 2026, to seek shareholder approval for a preferential allotment of equity shares worth ₹15.00 crores. The board of directors had earlier approved the proposal on December 11, 2025.

EGM Details and Voting Process

The company will conduct the EGM through Video Conferencing/Other Audio-Visual Means (OAVM) at 3:30 P.M. on January 9, 2026, in compliance with MCA and SEBI circulars. The cut-off date for determining voting eligibility has been set as January 2, 2026.

EGM Parameters	Details
Meeting Date	January 9, 2026
Time	3:30 P.M.
Mode	Video Conferencing/OAVM
Cut-off Date	January 2, 2026
Remote E-voting Period	January 6-8, 2026

Share Allotment Structure

The preferential issue involves 25,00,000 equity shares priced at ₹60.00 each, comprising a face value of ₹10.00 and premium of ₹50.00 per share. The allotment covers 40 investors across promoter group and non-promoter categories.

Issue Details	Specifications
Total Shares	25,00,000 equity shares
Issue Price	₹60.00 per share
Face Value	₹10.00
Premium	₹50.00
Total Amount	₹15,00,00,000
Number of Allottees	40 investors

Major Investor Allocations

The largest individual allocation goes to non-promoter Venkata Ramana Reddy Mallela with 3,30,000 shares, followed by promoter group member Pavani Vupparapalli receiving 3,25,000 shares. Other significant allocations include promoter Venkata Rama Rao Bommaraju (2,00,000 shares) and Avinash Reddy Pandiri (1,20,000 shares).

Top Allottees	Category	Shares Allocated
Venkata Ramana Reddy Mallela	Non-Promoter	3,30,000
Pavani Vupparapalli	Promoter Group	3,25,000
Venkata Rama Rao Bommaraju	Promoter	2,00,000
Avinash Reddy Pandiri	Non-Promoter	1,20,000

Fund Utilization Plan

The company plans to utilize the raised funds for lab-scale technology transfer expenses, laboratory interior setup, procurement of equipment including bio-reactors, and essential consumables. Additional allocations include technical expert expenses, pre-operative costs, working capital requirements, and general corporate purposes.

Fund Allocation	Amount (₹ Lakhs)	Timeline
Technology Transfer	30.00	Before June 30, 2026
Interior Setup	275.00	Before June 30, 2026
Lab Equipment	350.00	Before June 30, 2026
Bio-reactors	180.00	Before June 30, 2026
Technical Expenses	54.00	Before June 30, 2026
Working Capital	300.00	As required

Regulatory Compliance and Approvals

The preferential allotment requires shareholder approval through special resolution and compliance with SEBI (ICDR) Regulations, 2018. The company has appointed Bharat Khaniwal, Practicing Company Secretary (ACS-29035), as scrutinizer for the e-voting process. The relevant date for pricing determination has been fixed as December 10, 2025, with the minimum issue price calculated at ₹59.61 based on SEBI regulations.

Additional Business Item

The EGM agenda also includes confirmation of Ms. Sridevi Belide's appointment as Non-Executive Non-Independent Director. She was initially appointed as additional director on October 23, 2025, and holds an MBBS degree, bringing healthcare expertise to the board.